Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics

  1. Kunle Odunsi1,†,*,
  2. Robert M. Wollman2,
  3. Christine B. Ambrosone3,
  4. Alan Hutson5,
  5. Susan E. McCann3,
  6. Jonathan Tammela1,
  7. John P. Geisler6,
  8. Gregory Miller6,
  9. Thomas Sellers7,
  10. William Cliby8,
  11. Feng Qian1,
  12. Bernadette Keitz1,
  13. Marilyn Intengan4,
  14. Shashikant Lele1,
  15. James L. Alderfer2

Article first published online: 21 OCT 2004

DOI: 10.1002/ijc.20651

Issue

International Journal of Cancer

International Journal of Cancer

Volume 113, Issue 5, pages 782–788, 20 February 2005

Additional Information

How to Cite

Odunsi, K., Wollman, R. M., Ambrosone, C. B., Hutson, A., McCann, S. E., Tammela, J., Geisler, J. P., Miller, G., Sellers, T., Cliby, W., Qian, F., Keitz, B., Intengan, M., Lele, S. and Alderfer, J. L. (2005), Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer, 113: 782–788. doi: 10.1002/ijc.20651

Author Information

  1. 1

    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

  2. 2

    Division of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo, NY, USA

  3. 3

    Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA

  4. 4

    Division of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA

  5. 5

    Department of Biostatistics, University at Buffalo, Buffalo, NY, USA

  6. 6

    Department of Gynecologic Oncology, St. Vincent's Hospital, Indianapolis, IN, USA

  7. 7

    H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

  8. 8

    Department of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA

  1. †

    Fax: +716-845-7608.

*Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14261

Publication History

  1. Issue published online: 8 DEC 2004
  2. Article first published online: 21 OCT 2004
  3. Manuscript Accepted: 1 JUL 2004
  4. Manuscript Received: 24 OCT 2003

Funded by

  • Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative Grant
  • Roswell Park Cancer Center Support. Grant Number: P30CA16056
  • NYSTAR faculty development grant
  • NCI. Grant Number: KO7CA89123

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (130K)

References

  • 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36.
    Direct Link:
  • 2
    Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7.
  • 3
    NHS Centre for Reviews and Dissemination. Screening for ovarian cancer. Database of Abstracts of Reviews of Effectiveness, 2003.
  • 4
    van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77: 350–6.
  • 5
    Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, Bast RC Jr, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76(10 Suppl ): 2004–10.
    Direct Link:
  • 6
    Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC Jr. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999; 73: 56–61.
  • 7
    McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002; 11: 159–66.
  • 8
    Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995; 76(10 Suppl ): 2092–6.
    Direct Link:
  • 9
    Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207–10.
  • 10
    Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7.
  • 11
    Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 1993; 82: 946–50.
  • 12
    Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719–23.
  • 13
    Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671–9.
  • 14
    Gabrielson E, Berg K, Anbazhagan R. Functional genomics, gene arrays, and the future of pathology. Mod Pathol 2001; 14: 1294–9.
  • 15
    Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572–7.
  • 16
    Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181–9.
  • 17
    Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153–61.
  • 18
    Lindon JC, Nicholson JK, Everett JR. NMR spectroscopy of biofluids. Annu Rep NMR Spectrosc 1999; 38: 1–88.
  • 19
    Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 2000; 12: 289–320.
    Direct Link:
  • 20
    Holmes E, Nicholls AW, Lindon JC, Ramos S, Spraul M, Neidig P, Connor SC, Connelly J, Damment SJ, Haselden J, Nicholson JK. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 1998; 11: 235–44.
    Direct Link:
  • 21
    Holmes E, Nicholls AW, Lindon JC, Connor SC, Connelly JC, Haselden JN, Damment SJ, Spraul M, Neidig P, Nicholson JK. Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Toxicol 2000; 13: 471–8.
  • 22
    Wold S, Antti H, Lindgren F, Ohman J. Orthogonal signal correction of near-infrared spectra. Chemom Intell Lab Syst 1998; 44: 175–85.
  • 23
    Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Introduction to multi- and megavariate data analysis using projection methods (PCA & PLS). Umea, Sweden: Umetrics, 1999.
  • 24
    Coomans D, Broeckaert I, Derde MP, Tassin A, Massart DL, Wold S. Use of a microcomputer for the definition of multivariate confidence regions in medical diagnosis based on clinical laboratory profiles. Comput Biomed Res 1984; 17: 1–14.
  • 25
    Pepe MS. A regression modeling framework for receiver operating characteristic curves in medical diagnostic testing. Biometrika 1997; 84: 595–608.
  • 26
    Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 2000; 484: 169–74.
  • 27
    Pretsch E, Seibl J, Simon W, Clerc T. Spectral data for structure determination of organic compounds. Berlin: Springer-Verlag, 1989.
  • 28
    Fan W. Metabolite profiling by one- and two-dimensional NMR analysis of complex mistures. Prog NMR Spectrosc 1996; 28: 161–219.
  • 29
    Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995; 67: 793–811.
  • 30
    Ala-Korpela M. 1H-NMR spectroscopy of human blood plasma. Prog Nucl Magn Reson Spectrosc 1995; 27: 475–554.
  • 31
    Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog Nucl Magn Reson Spectrosc 1989; 21: 449–501.
  • 32
    Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Magn Reson Spectrosc 2001; 39: 1–40.
  • 33
    Holmes E, Nicholson JK, Tranter G. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem Res Toxicol 2001; 14: 182–91.
  • 34
    Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–9.
  • 35
    Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439–44.
  • 36
    Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003; 128: 32–6.
  • 37
    Fossel ET, Carr JM, McDonagh J. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986; 315: 1369–76.
  • 38
    Chmurny GN, Hilton BD, Halverson D, McGregor GN, Klose J, Issaq HJ, Muschik GM, Urba WJ, Mellini ML, Costello R, Papadopoulos NM, Caporaso N, et al. An NMR blood test for cancer: a critical assessment. NMR Biomed 1988; 1: 136–50.
    Direct Link:
  • 39
    Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054–61.]]
View Full Article (HTML) Get PDF (130K)